Clinical trial
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or…
NCT00470301 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00470301 |
|---|---|
| Title | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer |
| Official title | A Phase I-II Study of R115777 (Tipifarnib, Zarnestra®) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer |
| Intervention type | Drug |
| Interventions | tipifarnib, paclitaxel, doxorubicin, cyclophosphamide |
| Enrollment | 60 |
| Start date | Apr 1, 2007 |
| Primary completion | Sep 1, 2013 |
| Completion | Sep 1, 2013 |
| First posted | May 7, 2007 |
| Last update posted | Feb 16, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: